|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SRPRA |
Gene summary for SRPRA |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SRPRA | Gene ID | 6734 |
| Gene name | SRP receptor subunit alpha | |
| Gene Alias | DP | |
| Cytomap | 11q24.2 | |
| Gene Type | protein-coding | GO ID | GO:0006605 | UniProtAcc | P08240 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 6734 | SRPRA | LZE4T | Human | Esophagus | ESCC | 4.18e-13 | 3.99e-01 | 0.0811 |
| 6734 | SRPRA | LZE5T | Human | Esophagus | ESCC | 8.92e-05 | 4.86e-01 | 0.0514 |
| 6734 | SRPRA | LZE7T | Human | Esophagus | ESCC | 2.20e-04 | 4.11e-01 | 0.0667 |
| 6734 | SRPRA | LZE8T | Human | Esophagus | ESCC | 3.61e-03 | 1.68e-01 | 0.067 |
| 6734 | SRPRA | LZE20T | Human | Esophagus | ESCC | 1.37e-11 | 3.93e-01 | 0.0662 |
| 6734 | SRPRA | LZE22T | Human | Esophagus | ESCC | 3.05e-03 | 1.36e-02 | 0.068 |
| 6734 | SRPRA | LZE24T | Human | Esophagus | ESCC | 6.07e-24 | 7.59e-01 | 0.0596 |
| 6734 | SRPRA | LZE21T | Human | Esophagus | ESCC | 2.05e-03 | 4.50e-02 | 0.0655 |
| 6734 | SRPRA | P1T-E | Human | Esophagus | ESCC | 4.64e-03 | 5.28e-01 | 0.0875 |
| 6734 | SRPRA | P2T-E | Human | Esophagus | ESCC | 6.37e-20 | 3.75e-01 | 0.1177 |
| 6734 | SRPRA | P4T-E | Human | Esophagus | ESCC | 4.32e-41 | 1.23e+00 | 0.1323 |
| 6734 | SRPRA | P5T-E | Human | Esophagus | ESCC | 2.01e-25 | 5.42e-01 | 0.1327 |
| 6734 | SRPRA | P8T-E | Human | Esophagus | ESCC | 2.76e-24 | 5.62e-01 | 0.0889 |
| 6734 | SRPRA | P9T-E | Human | Esophagus | ESCC | 6.91e-25 | 4.84e-01 | 0.1131 |
| 6734 | SRPRA | P10T-E | Human | Esophagus | ESCC | 4.41e-22 | 5.42e-01 | 0.116 |
| 6734 | SRPRA | P11T-E | Human | Esophagus | ESCC | 3.50e-18 | 9.15e-01 | 0.1426 |
| 6734 | SRPRA | P12T-E | Human | Esophagus | ESCC | 2.95e-26 | 6.19e-01 | 0.1122 |
| 6734 | SRPRA | P15T-E | Human | Esophagus | ESCC | 9.50e-17 | 3.95e-01 | 0.1149 |
| 6734 | SRPRA | P16T-E | Human | Esophagus | ESCC | 8.89e-26 | 6.89e-01 | 0.1153 |
| 6734 | SRPRA | P17T-E | Human | Esophagus | ESCC | 9.25e-09 | 5.39e-01 | 0.1278 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Stomach | WIM |  |
| Stomach | SIM |  |
| Liver | NAFLD |  |
| Liver | Cirrhotic |  |
| Liver | HCC |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0072594110 | Esophagus | ESCC | establishment of protein localization to organelle | 311/8552 | 422/18723 | 3.02e-32 | 2.13e-29 | 311 |
| GO:0006605111 | Esophagus | ESCC | protein targeting | 229/8552 | 314/18723 | 4.93e-23 | 1.01e-20 | 229 |
| GO:0090150110 | Esophagus | ESCC | establishment of protein localization to membrane | 182/8552 | 260/18723 | 1.27e-15 | 8.19e-14 | 182 |
| GO:007097218 | Esophagus | ESCC | protein localization to endoplasmic reticulum | 52/8552 | 74/18723 | 1.58e-05 | 1.42e-04 | 52 |
| GO:00066124 | Esophagus | ESCC | protein targeting to membrane | 83/8552 | 131/18723 | 3.31e-05 | 2.73e-04 | 83 |
| GO:007259915 | Esophagus | ESCC | establishment of protein localization to endoplasmic reticulum | 31/8552 | 46/18723 | 2.42e-03 | 1.06e-02 | 31 |
| GO:004504715 | Esophagus | ESCC | protein targeting to ER | 28/8552 | 42/18723 | 4.90e-03 | 1.89e-02 | 28 |
| GO:007259412 | Liver | Cirrhotic | establishment of protein localization to organelle | 189/4634 | 422/18723 | 1.01e-19 | 2.45e-17 | 189 |
| GO:00066057 | Liver | Cirrhotic | protein targeting | 148/4634 | 314/18723 | 3.86e-18 | 6.20e-16 | 148 |
| GO:00901507 | Liver | Cirrhotic | establishment of protein localization to membrane | 123/4634 | 260/18723 | 1.85e-15 | 2.15e-13 | 123 |
| GO:00709724 | Liver | Cirrhotic | protein localization to endoplasmic reticulum | 45/4634 | 74/18723 | 4.79e-11 | 2.73e-09 | 45 |
| GO:00725994 | Liver | Cirrhotic | establishment of protein localization to endoplasmic reticulum | 26/4634 | 46/18723 | 4.14e-06 | 6.94e-05 | 26 |
| GO:00450474 | Liver | Cirrhotic | protein targeting to ER | 24/4634 | 42/18723 | 7.49e-06 | 1.15e-04 | 24 |
| GO:00066122 | Liver | Cirrhotic | protein targeting to membrane | 53/4634 | 131/18723 | 5.17e-05 | 5.95e-04 | 53 |
| GO:00066132 | Liver | Cirrhotic | cotranslational protein targeting to membrane | 17/4634 | 31/18723 | 3.19e-04 | 2.77e-03 | 17 |
| GO:007259422 | Liver | HCC | establishment of protein localization to organelle | 299/7958 | 422/18723 | 1.06e-32 | 6.10e-30 | 299 |
| GO:000660512 | Liver | HCC | protein targeting | 219/7958 | 314/18723 | 7.74e-23 | 1.49e-20 | 219 |
| GO:009015012 | Liver | HCC | establishment of protein localization to membrane | 168/7958 | 260/18723 | 4.07e-13 | 2.13e-11 | 168 |
| GO:007097212 | Liver | HCC | protein localization to endoplasmic reticulum | 54/7958 | 74/18723 | 1.01e-07 | 1.98e-06 | 54 |
| GO:007259911 | Liver | HCC | establishment of protein localization to endoplasmic reticulum | 34/7958 | 46/18723 | 1.53e-05 | 1.67e-04 | 34 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0306026 | Esophagus | ESCC | Protein export | 22/4205 | 23/8465 | 2.43e-06 | 1.43e-05 | 7.32e-06 | 22 |
| hsa0306036 | Esophagus | ESCC | Protein export | 22/4205 | 23/8465 | 2.43e-06 | 1.43e-05 | 7.32e-06 | 22 |
| hsa030608 | Liver | Cirrhotic | Protein export | 20/2530 | 23/8465 | 2.00e-08 | 3.51e-07 | 2.17e-07 | 20 |
| hsa0306011 | Liver | Cirrhotic | Protein export | 20/2530 | 23/8465 | 2.00e-08 | 3.51e-07 | 2.17e-07 | 20 |
| hsa0306021 | Liver | HCC | Protein export | 21/4020 | 23/8465 | 1.20e-05 | 8.53e-05 | 4.74e-05 | 21 |
| hsa0306031 | Liver | HCC | Protein export | 21/4020 | 23/8465 | 1.20e-05 | 8.53e-05 | 4.74e-05 | 21 |
| hsa0306018 | Oral cavity | OSCC | Protein export | 21/3704 | 23/8465 | 2.42e-06 | 1.27e-05 | 6.45e-06 | 21 |
| hsa0306019 | Oral cavity | OSCC | Protein export | 21/3704 | 23/8465 | 2.42e-06 | 1.27e-05 | 6.45e-06 | 21 |
| hsa0306025 | Oral cavity | LP | Protein export | 21/2418 | 23/8465 | 4.72e-10 | 8.28e-09 | 5.34e-09 | 21 |
| hsa0306035 | Oral cavity | LP | Protein export | 21/2418 | 23/8465 | 4.72e-10 | 8.28e-09 | 5.34e-09 | 21 |
| hsa0306016 | Prostate | BPH | Protein export | 18/1718 | 23/8465 | 3.72e-09 | 5.11e-08 | 3.16e-08 | 18 |
| hsa0306017 | Prostate | BPH | Protein export | 18/1718 | 23/8465 | 3.72e-09 | 5.11e-08 | 3.16e-08 | 18 |
| hsa0306024 | Prostate | Tumor | Protein export | 18/1791 | 23/8465 | 7.50e-09 | 1.03e-07 | 6.42e-08 | 18 |
| hsa0306034 | Prostate | Tumor | Protein export | 18/1791 | 23/8465 | 7.50e-09 | 1.03e-07 | 6.42e-08 | 18 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SRPRA | SNV | Missense_Mutation | c.219C>G | p.Ile73Met | p.I73M | P08240 | protein_coding | deleterious(0.04) | possibly_damaging(0.606) | TCGA-BH-A0DZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD | |
| SRPRA | SNV | Missense_Mutation | c.175G>A | p.Asp59Asn | p.D59N | P08240 | protein_coding | deleterious(0) | probably_damaging(0.973) | TCGA-BH-A0DZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD | |
| SRPRA | SNV | Missense_Mutation | c.787N>G | p.Thr263Ala | p.T263A | P08240 | protein_coding | tolerated(0.59) | benign(0) | TCGA-BH-A1EV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
| SRPRA | SNV | Missense_Mutation | rs778409990 | c.1385N>C | p.Val462Ala | p.V462A | P08240 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C8-A12M-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SRPRA | SNV | Missense_Mutation | c.1864N>A | p.Asp622Asn | p.D622N | P08240 | protein_coding | deleterious(0) | probably_damaging(0.971) | TCGA-C8-A12T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| SRPRA | SNV | Missense_Mutation | rs370707916 | c.1867N>G | p.Leu623Val | p.L623V | P08240 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-E9-A22E-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphane | SD |
| SRPRA | SNV | Missense_Mutation | c.583N>T | p.Pro195Ser | p.P195S | P08240 | protein_coding | tolerated(0.21) | benign(0) | TCGA-EW-A1P3-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD | |
| SRPRA | insertion | Frame_Shift_Ins | novel | c.1419_1420insTCCCTTTACAACTTGA | p.Ala474SerfsTer23 | p.A474Sfs*23 | P08240 | protein_coding | TCGA-A8-A090-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| SRPRA | insertion | Frame_Shift_Ins | novel | c.1829_1830insTGTCTTCAGTGTAGTACAAAGGCAGAGTGAGGGGGCTTGTGGCT | p.Ile611ValfsTer41 | p.I611Vfs*41 | P08240 | protein_coding | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| SRPRA | SNV | Missense_Mutation | rs558045090 | c.391N>T | p.Arg131Cys | p.R131C | P08240 | protein_coding | deleterious(0) | benign(0.052) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |